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Abstract. It is generally assumed that anticholinergic drugs have no effects on 
schizophrenic symptomatology. A few studies, however, indicate that anti- 
cholinergic agents aggravate psychotic symptoms and antagonize therapeutic 
effects of neuroleptics in schizophrenic patients; more recently, some investigators 
have observed that these agents appear to benefit negative symptoms. In an effort 
to resolve this issue, we studied the effects of 2 days of treatment with biperiden on 
positive and negative symptoms in 15 medication-free schizophrenic patients. 
Positive symptoms increased significantly, while there was a trend toward a 
decrease in negative symptoms. The implications of these findings for the role of 
the cholinergic system in schizophrenia are discussed. 
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Anticholinergic drugs are commonly used in the treatment of extrapyramidal side 
effects, which frequently accompany neuroleptic treatment in schizophrenia. It is 
assumed that anticholinergic drugs do not affect schizophrenic symptomatology, and 
general clinical experience is consistent with this assumption. There were some early 
reports, however, of anticholinergic drugs exacerbating psychotic symptomatology in 
schizophrenic patients (Gershon and Olariu, 1960; Itil et al., 1969). These observations 
have been supported by several recent studies showing that antimuscariniclanti- 
cholinergic agents may antagonize the therapeutic effects of neuroleptics in schizo- 
phrenia (Singh and Kay, 1979; Johnstone et al., 1983, 1988; Singh et al., 1987). The 
adverse effects of anticholinergic drugs in schizophrenia are reportedly confined to 
positive symptoms, without any effects on negative symptoms. In fact, some recent 
studies indicate that trihexiphenidyl, an antimuscarinic agent, may actually have 
beneficial effects on negative schizophrenic symptoms (Fayen et al., 1988; Tandon et 
al., 1988). 
In view of the frequent use of anticholinergic agents in schizophrenia, the dearth of 
controlled studies on the effects of anticholinergic drugs on symptomatology in 
medication-free schizophrenic patients is surprising. In this study, we examined the 
effects of biperiden, a relatively specific M, antimuscarinic/anticholinergic agent, on 
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positive and negative symptoms in 15 schizophrenic inpatients who were otherwise 
free of medication. 
Methods 
Patients and Study Design. The sample consisted of 15 consecutively hospitalized patients 
who were admitted to the Schizophrenia Inpatient Program at the University of Michigan. 
Diagnostic evaluation included a structured interview using the Schedule for Affective Dis- 
orders and Schizophrenia (SADS; Endicott and Spitzer, 1978), as well as all available history 
and clinical observations. Patients had to meet both DSM-III-R criteria(American Psychiatric 
Association, 1987) and Research Diagnostic Criteria(RDC; Spitzeret al., 1978) for inclusion in 
the study. The sample consisted of 11 men and 4 women with a mean age of 29 (SD = 6) years and 
a mean duration of illness of 6 (SD q 4) years. All of the patients were free of medical disorders. 
None of them had received depot neuroleptics for at least 6 months before entering the study. 
After having been maintained in a medication-free state for at least 2 weeks, patients received 
4 mg of biperiden on night 1, two doses of 4 mg biperiden the next day, and a 4 mg morning dose 
of biperiden on day 3. Two nurse-clinician raters (N.A.M. and W.H.E.), without knowledge of 
patients’ medication status and the rationale of the study, independently rated the patients on 
the 18-item Brief Psychiatric Rating Scale (BPRS; Overall and Gorham, 1962) before starting 
biperiden on day 1 (baseline) and day 3 (postbiperiden). Scores on BPRS items assessing motor 
retardation, blunted affect, and emotional withdrawal (rated 1 for not present to 7 for severe) 
were summed and used as the BPRS negative symptom cluster. These items collectively 
constitute the “ANER” factor (Guy, 1976; Hedlund and Viewig, 1980). The BPRS items 
assessing conceptual disorganization, suspiciousness, hallucinatory behavior, and unusual 
thought content were summed as the BPRS positive symptom cluster. The BPRS was used to 
rate positive and negative symptomatology because it is a reliable, sensitive, and effective 
measure of psychopathology and of treatment-related symptom changes (Hedlund and Viewig, 
1980). 
Biperiden was used as the antimuscarinic/anticholinergic agent because, as a relatively 
specific M, antimuscarinic antagonist (Syvalalrti et al., 1987; Eltze and Figala, 1988) it causes 
significantly fewer peripheral anticholinergic side effects than other commonly used oral 
anticholinergic agents and is better tolerated (Avissar and Schreiber, 1989). Furthermore, M, 
receptors are located in the brain areas considered relevant in schizophrenia (Bonner et al., 
1987; Watson et al., 1987) and are thus the receptor system most likely to be implicated in 
schizophrenic symptomatology. Since the usual daily dosage of biperiden in the treatment of 
parkinsonian symptoms is 4-12 mg/day, we elected to use 8 mg in two divided doses. The 3-day 
duration of the study was selected because (1) the effect of a single dose on symptomatology may 
be limited by the inability of the system to respond this quickly to anticholinergic modulation; 
and (2) compensatory changes to the initial primary effect of biperiden might occur over a 
longer period, thereby interfering with the evaluation of the primary effect. 
Data Analysis. Paired two-tailed r tests were performed to compare the symptom ratings at 
baseline to those in the postbiperiden phase. 
Results 
The BPRS total scores at baseline ranged from 35 to 72 (mean = 48.2, SD = 12.3). In 
this study, interrater reliability coefficients (measured by the Pearson product- 
moment correlations) between the two independent raters (N.A.M. and W.H.E.) for 
the 18 individual BPRS items ranged from 0.70 to 0.95, with a median of 0.85. The 
interrater reliability coefficients for the positive and negative symptom clusters were 
0.92 and 0.87, respectively. 
Baseline positive symptom cluster scores ranged from 7 to 20 (mean = 12.8, SD = 
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3.6). There was a significant increase inpositivesymprom severity following biperiden 
(t = 4.4, df= 14,~ < O.Ol), with postbiperiden positive symptom cluster scores ranging 
from 6 to 22 (mean q 15.7, SD = 4.4). (See Fig. 1.) 
Baseline negative symptom cluster scores ranged from 3.5 to 16.5 (mean = 9.0, SD = 
3.7). There was a trend toward a decrease in negative symptom severity following 
biperiden (t = -1.9, df= 14, p = 0.08), with postbiperiden negative symptom cluster 
scores ranging from 4 to 14 (mean = 7.9, SD = 3.0). (See Fig. 1.) There was no 
association between changes in positive and negative symptom severity (r = 0.27, n = 
15, NS). 
Daily monitoring of patients’ clinical status by their respective primary nurses 
(different from the nurse-clinician raters) was consistent with the changes in positive 
and negative symptoms noted on the BPRS. After biperiden, patients were reported as 
being more “open,” expressive, engaging, and communicative. The primary nurses 
also noted an increased reporting of positive symptomatology (e.g., delusions and 
hallucinations) by the patients, which they ascribed to their increased “openness” and 
expressiveness, 
Fig. 1. Change in positive and negative symptoms following biperiden in 





The finding that the severity of positive symptoms increases following the administra- 
tion of biperiden to medication-free schizophrenic patients is consistent with previous 
reports of aggravation of psychotic symptomatology (Gershon and Olariu, 1960; Itil et 
al., 1969) and antagonism of the therapeutic effects of neuroleptics on positive 
symptoms (Haase, 1965; Singh and Kay, 1979; Johnstone et al., 1983, 1988; Singh et 
al., 1987) in schizophrenic patients by anticholinergic agents. On the other hand, 
several studies have demonstrated that abrupt or gradual withdrawal of anti- 
cholinergic drugs has no salutary effect on schizophrenic symptoms and, in fact, may 
occasionally be associated with a worsening of the clinical state (Ananth et al., 1970; 
McClelland et al., 1974; Rifkin et al., 1975; Jellinek et al., 1981; Manos et al., 1981). A 
review of the literature reveals that studies showing no adverse effects of anti- 
cholinergic drugs and no improvement following anticholinergic withdrawal in 
schizophrenic patients were conducted in the chronic neuroleptic-stabilized phase of 
the illness, while investigations documenting adverse effects of anticholinergic drugs 
on positive symptoms were conducted in the acute phase of the illness. In any event, 
virtually all these studies were conducted in schizophrenic patients receiving neuro- 
leptics, and any effect of reducing cholinergic activity could have been obscured by the 
simultaneously decreased dopaminergic activity due to the neuroleptic. In the present 
study, the effects of biperiden were evaluated in otherwise medication-free patients, 
thereby eliminating the “confounding” effect of neuroleptic medication. The impor- 
tance of disturbances in dopaminergic/cholinergic balance in the expression of posi- 
tive schizophrenic symptoms is supported by the finding that the exacerbation in 
positive symptoms produced by methylphenidate (an agent that enhances dopamine 
neurotransmission) in schizophrenic patients is reversed by physostigmine (an agent 
that enhances cholinergic neurotransmission) (Janowsky et al., 1973). 
While positive symptoms increased following biperiden, negative symptoms 
showed a tendency to decrease. The observed reduction in negative symptoms with 
biperiden is consistent with previous reports of beneficial effects of anticholinergic 
agents on negative schizophrenic symptoms (Fayen et al., 1988; Tandon et al., 1988). 
In these earlier studies, however, patients were also receiving neuroleptic drugs, 
raising the possibility that the beneficial effects of the anticholinergic agents were 
related to relief of akinesia, despite the absence of any overt extrapyramidal side 
effects. The present study, in which patients were medication free except for the “study 
drug” biperiden, makes that interpretation less likely. 
In view of the covariance of positive and negative symptoms in the psychotic phase 
of schizophrenia and their concomitant response to neuroleptic treatment (Goldberg, 
1985; Breier et al., 1987; van Kammen et al., 1987; Goldman and Tandon, 1989; Kay 
and Singh, 1989; Keefe et al., 1989), our findings of an increase in positive symptoms 
and a decrease in negative symptoms following a reduction in cholinergic activity 
(with biperiden) appear puzzling. They are, however, consistent with and predictable 
from the recently proposed model of dopaminergic/ cholinergic interactions in schizo- 
phrenia (Tandon and Greden, 1989, in press). This model suggests that (1) cholinergic- 
dopaminergic balance is of central importance in schizophrenic pathophysiology; (2) 
muscarinic activity increases in an attempt to maintain this balance in the face of 
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increasing dopaminergic activity that occurs in the psychotic phase of the illness; (3) 
the muscarinic/cholinergic system exerts a damping effect on the emergence of 
positive symptoms associated with dopaminergic hyperactivity; and (4) this compen- 
satory increase in muscarinic activity is in turn accompanied by an intensification of 
negative symptoms during and following the psychotic phase of the illness. 
Reducing cholinergic activity without concomitantly decreasing dopaminergic 
activity (as in the present study) would be expected to increase positive symptoms, as 
the cholinergic system may afford protection against the emergence of positive symp- 
toms associated with dopaminergic hyperactivity. At the same time, decreasing choli- 
nergic activity would be expected to result in a reduction of negative symptoms (as the 
“compensatory” cholinergic hyperactivity is implicated as a major mechanism in the 
production of negative symptoms at this phase of the illness). On the other hand, both 
positive and negative symptoms would be expected to improve with neuroleptic 
treatment. As dopaminergic activity decreases with neuroleptic treatment (and posi- 
tive symptoms improve), there should be a corresponding reduction in muscarinic 
activity, since an increase in muscarinic activity presumably occurred as a “compensa- 
tory” response to the increased dopaminergic activity in this phase of the illness. This 
reduction in muscarinic/ cholinergic activity would be accompanied by an improve- 
ment in negative symptoms. 
Several methodological issues deserve comment: (1) Anticholinergic drugs, particu- 
larly benztropine, may cause dopamine release and block reuptake (thereby increasing 
central dopaminergic activity) (Horn et al., 1971; Model1 et al, 1989). Thus, the 
increase in positive symptoms and the decrease in negative symptoms with biperiden 
could possibly be ascribed to its dopaminergic rather than its anticholinergic property. 
Commonly used anticholinergic drugs other than benztropine, however, have very 
weak effects on the dopamine and other catecholamine receptors, and biperiden has 
the least potent activity in this regard (Horn et al., 197 1). While it is therefore unlikely 
that the observed effects of biperiden on positive and negative symptoms are related to 
its insignificant dopaminergic activity, this alternative explanation cannot be com- 
pletely dismissed. (2) While the increase in positive symptoms that occurred with 
biperiden was very highly significant, the decrease in negative symptoms only showed 
a trend toward significance (JJ = 0.08). Whether this reflects the need for a larger 
sample, limitations of our instruments, or absence of a real effect needs to be evaluated 
in future studies. Even if these effects of an anticholinergic agent on positive and 
negative symptoms were confirmed, the clinical relevance of such findings would 
require further evaluation. (3) These findings must be considered preliminary and 
require corroboration in larger samples with a placebo-controlled design. 
If these findings are confirmed, they have important pathophysiological implica- 
tions for the role of the cholinergic system in schizophrenia. They may also have 
implications for therapy in view of (1) the widespread use of anticholinergic agents in 
the treatment of extrapyramidal side effects of neuroleptics and (2) the fact that many 
neuroleptic drugs also have potent anticholinergic effects. 
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